Navigation Links
Cepheid Reports 2013 Second Quarter Results

SUNNYVALE, Calif., July 18, 2013 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today reported revenues for the second quarter of 2013 of $96.0 million, representing growth of 19% from $81.0 million for the second quarter of 2012.  Net loss in the second quarter of 2013 was $6.6 million, or $(0.10) per share, which compares to net income of $1.1 million, or $0.02 per share, in the second quarter of 2012. 

Excluding employee stock-based compensation and amortization of purchased intangible assets, non-GAAP net income for the second quarter of 2013 was $1.2 million, or $0.02 per share.  This compares to non-GAAP net income of $7.9 million, or $0.11 per share, in the second quarter of 2012.

As discussed in Cepheid's press release dated July 11, 2013, second quarter results reflect an unanticipated inventory reserve of approximately $3.0 million, which impacted earnings per share by approximately $0.04. 

"With a record 435 systems placed in the second quarter, it is clear that the GeneXpert® system is gaining momentum in both commercial and HBDC markets as the molecular platform of choice," said John Bishop, Cepheid's Chairman and Chief Executive Officer.  "With backorders of Xpert® test cartridges now behind us, and with new leadership and a new organizational structure in manufacturing operations, we are investing aggressively and driving across-the-board improvements to ensure that Cepheid is well prepared to effectively manage the growing demand for our rapidly expanding Xpert test menu." 

Operational Overview

  • By business, total sales were, in millions:
  • Three Months Ended June 30,20132012ChangeClinical Systems

    3.920%Clinical Reagents

    70.855.827%Total Clinical 87.569.726%Non-Clinical & Other

    8.511.3-25%Total Sales$

  • By geography, total sales were, in millions:
  • Three Months Ended June 30,20132012ChangeNorth AmericaClinical

    47.55%Non-Clinical & Other

    7.59.5-21%Total North America57.457.01%InternationalClinical

    37.622.269%Non-Clinical & Other

    1.01.8-41%Total International38.624.061%Total Sales$

  • During the quarter, Cepheid installed a total of 156 GeneXpert systems in its commercial Clinical business.  Additionally, the Company placed a total of 279 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.  Including the HBDC systems, a cumulative total of 4,552 GeneXpert systems have been placed worldwide as of June 30, 2013.
  • GAAP gross margin on sales was 45% and non-GAAP gross margin on sales was 47%, which compares to 57% and 58%, respectively, in the second quarter of 2012.  Excluding the impact of the unanticipated inventory reserve of approximately $3.0 million, GAAP gross margin on sales was 48% and non-GAAP gross margin on sales was 50%.
  • Cash and cash equivalents were $85.0 million as of June 30, 2013.
  • DSO was 45 days.
  • Business OutlookFor the fiscal year ending December 31, 2013, the Company's full year guidance has been revised to reflect additional investment in manufacturing operations to fully prepare the Company to effectively manage growing demand and expected revenue mix between Commercial Clinical and HBDC.  With these points in mind, the Company now expects:

  • Total revenue in the range of $380 to $385 million;
  • Net loss in a range from $(0.30) to $(0.27) per share; and
  • Non-GAAP net income in the range of $0.18 to $0.21 per share. 
  • Expected non-GAAP net income excludes approximately $29 million related to stock compensation expense and approximately $4 million related to the amortization of acquired intangibles.  The fully diluted share count for the year is expected to be approximately 67 million, except in the event we have non-GAAP net income, in which case the share count would be approximately 72 million shares.

    The following table reconciles net loss per share to the non-GAAP net income per share range:Guidance Range for YearEnding December 31, 2013Low HighNet Loss Per Share$
    (0.27)Stock Compensation Expense0.420.42Amortization of Purchased Intangible Assets0.060.06Non-GAAP Measure of Net Income Per Share$
    .21Accessing Cepheid's 2013 Second Quarter Results Conference CallThe Company will host a management presentation at 2 p.m. Pacific Time on Thursday, July 18, 2013, to discuss the results.  To access the live webcast, please visit Cepheid's website at at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

    About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the Company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the Company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit

    Use of Non-GAAP MeasuresThe Company has supplemented its reported GAAP financial information with non-GAAP measures that do not include employee stock-based compensation expense, amortization of purchased intangible assets and a tax benefit related to an intercompany intellectual property transaction.  The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with U.S. GAAP.
    The Company's management uses the non-GAAP information internally to evaluate its ongoing business, continuing operational performance and cash requirements, and believes these non-GAAP measures are useful to investors as they provide a basis for evaluating the Company's cash requirements and additional insight into the underlying operating results and the Company's ongoing performance in the ordinary course of its operations.

    These non-GAAP measures may be different from non-GAAP measures used by other companies.  In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.  The Company believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with its results of operations as determined in accordance with U.S. GAAP and that these measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures.

    As described above, the Company excludes the following items from one or more of its non-GAAP measures when applicable:

    Employee Stock-based Compensation Expense. These expenses consist primarily of expenses for employee stock options and employee restricted stock under ASC 718 (formerly SFAS 123(R)).  The Company excludes employee stock-based compensation expenses from its non-GAAP measures primarily because they are non-cash expenses that the Company does not believe are reflective of ongoing operating results in the period incurred.  Further, as the Company applies ASC 718, it believes that it is useful to investors to understand the impact of the application of ASC 718 on its results of operations.

    Amortization of Purchased Intangible Assets.  The Company incurs amortization of purchased intangible assets in connection with acquisitions.  The Company excludes these items because these expenses are not reflective of ongoing operating results in the period incurred.  These amounts arise from the Company's prior acquisitions and have no direct correlation to the operation of the Company's business.

    Tax Benefit Related to Intercompany Intellectual Property (IP) Transaction.  The Company excluded a tax benefit related to an intercompany IP transaction from its results for non-GAAP net loss for the first quarter ended March 31, 2012.  The Company excluded this item as it believes it is non-recurring in nature, and does not have a direct impact on the operation of the Company's core business. 

    Forward-Looking StatementsThis press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to potential growth, future revenues and future net loss/income and profitability, including on a non-GAAP basis, test menu expansion and utilization, consistency of product availability and delivery, sales organization productivity, improving gross margins, execution of manufacturing operations, product sales under the High Burden Developing Country (HBDC) program, commercial test and commercial system sales and resolution of manufacturing scale-up issues. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our ability to successfully complete and bring on line additional manufacturing lines; our ability to manage our inventory levels; long sales cycles and variability in systems placements and reagent pull-through in the Company's HBDC program; our success in increasing commercial and HBDC sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand, customer confidence in product availability and available customer budgets for our customers; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; other unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.

    All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

    Cepheid Corporate Communications

    Tel: (408) 400 8377

    Jacquie Ross

    Cepheid Investor Relations

    Tel: (408) 400 8329

    investor.relations@cepheid.comFINANCIAL TABLES FOLLOW CEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)Three Months Ended June
    30, Six Months Ended June
    30, 2013201220132012Sales:System and other sales

    32,330Reagent and disposable sales

    77,21663,915153,144125,977Total sales

    96,01281,015187,950158,307Costs and operating expenses:Cost of sales 

    52,88935,07295,78170,680Collaboration profit sharing 

    1,4251,6453,5353,329Research and development

    18,57216,11836,29938,220Sales and marketing

    19,10515,10838,23129,620General and administrative

    9,61211,01119,37522,062Total costs and operating expenses 

    101,60378,954193,221163,911Income (loss) from operations

    (5,591)2,061(5,271)(5,604)Other expense, net

    (717)(572)(343)(334)Income (loss) before income taxes

    (6,308)1,489(5,614)(5,938)Benefit from (provision for) income taxes

    (272)(354)(653)1,547Net income (loss)

    (4,391)Basic net income (loss) per share 

    (0.07)Diluted net income (loss) per share 

    (0.07)Shares used in computing basic net income (loss) per share 

    67,29565,69567,06165,361Shares used in computing diluted net income (loss) per share 

    67,29568,86967,06165,361CEPHEIDCONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS(in thousands)June 30, 2013December
    31, 2012
    ASSETSCurrent assets: Cash and cash equivalents

    $ 85,030$ 95,779 Accounts receivable, net

    47,82843,999 Inventory

    85,01070,114 Prepaid expenses and other current assets

    15,2639,448Total current assets

    233,131219,340Property and equipment, net

    66,23254,830Other non-current assets

    1,078913Intangible assets, net


    39,68137,694Total assets

    $ 358,638$ 331,544LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities: Accounts payable

    $ 40,436$ 33,701 Accrued compensation

    19,20416,540 Accrued royalties

    7,3307,992 Accrued and other liabilities

    4,0404,235 Current portion of deferred revenue

    11,3009,599 Current portion of notes payable

    183183Total current liabilities

    82,49372,250Long-term portion of deferred revenue

    8771,156Notes payable, less current portion

    1,5411,685Other liabilities

    9,7508,911Total liabilities

    94,66184,002Shareholders' equity: Common stock

    365,317355,867 Additional paid-in capital

    130,429117,217 Accumulated other comprehensive income

    9656 Accumulated deficit

    (231,865)(225,598)Total shareholders' equity

    263,977247,542Total liabilities and shareholders' equity

    June 30, 20132012Cash flows from operating activities:Net income (loss)

    (4,391)Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:Depreciation and amortization of property and equipment

    8,3616,308Amortization of intangible assets 

    3,1462,633Unrealized exchange differences

    575-Stock-based compensation related to employees and consulting services rendered

    12,80611,567Changes in operating assets and liabilities:Accounts receivable 


    (14,491)(5,950)Prepaid expenses and other current assets 

    (6,454)(7,475)Other non-current assets

    30(105)Accounts payable and other current liabilities 

    5,669(12,233)Accrued compensation 

    2,616(1,312)Deferred revenue 

    1,422438Net cash provided by (used in) operating activities 

    4,827(9,759)Cash flows from investing activities:Capital expenditures 

    (18,974)(11,168)Payments for technology licenses 

    (1,125)-Cost of acquisitions, net

    (3,571)(17,462)Net cash used in investing activities 

    (23,670)(28,630)Cash flows from financing activities:Net proceeds from the issuance of common shares and exercise of stock options

    9,45021,091Principal payment of notes payable

    (781)-Net cash provided by financing activities 

    8,66921,091Effect of exchange rate change on cash

    (575)(443)Net decrease in cash and cash equivalents 

    (10,749)(17,741)Cash and cash equivalents at beginning of period 

    95,779115,008Cash and cash equivalents at end of period

    97,267 CEPHEIDRECONCILIATION OF GAAP TO NON-GAAP MEASURES (UNAUDITED)(in thousands, except per share data)Three Months EndedJune 30,Six Months EndedJune 30,2013201220132012Cost of sales$
    70,680  Stock compensation expense(840)(700)(1,382)(1,335)  Amortization of purchased intangible assets(805)(333)(1,659)(666)Non-GAAP measure of cost of sales$
    8,679Gross margin on sales per GAAP45%57%49%55%Gross margin on sales per Non-GAAP47%58%51%57%Operating expenses$
    89,902  Stock compensation expense(5,689)(5,346)(11,424)(10,209)  Amortization of purchased intangible assets(441)(381)(815)(697)Non-GAAP measure of operating expenses$
    78,996Income (loss) from operations$
    (5,604)  Stock compensation expense6,5296,04612,80611,544  Amortization of purchased intangible assets1,2467142,4741,363Non-GAAP measure of income from operations$
    7,303Net income (loss)$
    (4,391)  Stock compensation expense6,5296,04612,80611,544  Amortization of purchased intangible assets1,2467142,4741,363  Tax benefit related to intercompany IP transaction---(1,815)Non-GAAP measure of net income$
    ,701Basic net income (loss) per share$
    (0.07)  Stock compensation expense0.  Amortization of purchased intangible assets0.  Tax benefit related to intercompany IP transaction---(0.03)Non-GAAP measure of net income per share$
    .10Diluted net income (loss) per share$
    (0.07)  Stock compensation expense0.  Amortization of purchased intangible assets0.  Tax benefit related to intercompany IP transaction---(0.03)Non-GAAP measure of net income per share$
    .10Shares used in computing basic net income (loss) per share67,29565,69567,06165,361Shares used in computing diluted net income (loss) per share69,66668,86969,55468,535

    SOURCE Cepheid
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Cepheid Welcomes Senior Vice President of Human Resources
    2. Cepheid Reports Fourth Quarter and Full Year 2011 Results
    3. Cepheid to Webcast Upcoming Financial Presentations
    4. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
    5. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
    6. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
    7. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
    8. Cepheid Reports 2012 Second Quarter Results
    9. Cepheid Announces Board of Directors Changes
    10. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
    11. Cepheid Reports 2013 First Quarter Results
    Post Your Comments:
    (Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
    (Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
    (Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
    (Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
    Breaking Biology Technology:
    (Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
    (Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
    (Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
    Breaking Biology News(10 mins):